P440Ehelp China, a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China
Open accessThe DOI matches its Crossref record.
Abstract
Introduction: Statins reduce low-density lipoprotein cholesterol (LDL-C) and thereby cardiovascular (CV) risk. However, in many countries, disease awareness, access to treatment and patient adherence are low, and treatment duration is often less than 3 months. Patient-focussed mobile health (mHealth) technology using smart phone apps has the potential to provide support to large numbers of patients at a cost that is sustainable over a long time. However, limited data exist on the impact of these tools. This is the first study to assess the impact of a mHealth tool on statin treatment duration and is an important step towards generation of evidence for patient focused mHealth. Purpose: A randomised, two-arm, open-label exploratory study to evaluate if a smart phone-based patient support tool prolongs statin treatment duration in patients at high CV risk. Methods: Patients newly prescribed a statin in China were randomised (1:1) to an Active group, which received the smart phone-based patient support tool or to a Control group, which received only a control app. Both groups completed a questionnaire specifically developed to evaluate adherence via their smart phone. The primary outcome was duration of statin treatment (time from randomisation to last patient-reported visit to a doctor for prescription renewal plus the number of days of the last prescription). Secondary outcomes were percentage of fully adherent patients, treatment adherence and percent change in LDL-C at Week 24.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The expanding regulatory mechanisms and cellular functions of circular RNAs
Chen, L.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0243-y · Cited by 1,713
Exosomal circRNAs: biogenesis, effect and application in human diseases
Wang, Y., Liu, J., Ma, J., Sun, T., Zhou, Q., Wang, W., Wang, G., Wu, P., Wang, H., Jiang, L., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1041-z · Cited by 636
Targeting circular RNAs as a therapeutic approach: current strategies and challenges
He, A. T., Liu, J., Li, F., & Yang, B. B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00569-5 · Cited by 549
Circular RNAs open a new chapter in cardiovascular biology
Aufiero, S., Reckman, Y. J., Pinto, Y. M., & Creemers, E. E. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0185-2 · Cited by 357
A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy
Du, W. W., Yang, W., Li, X., Awan, F. M., Yang, Z., Fang, L., Lyu, J., Li, F., Peng, C., Krylov, S. N., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0369-y · Cited by 335
Metadata
- Authors
- Du, X., Jornten-Karlsson, M., Xu, Y., Guo, J., Li, J., Mei, X., Han, L., Wang, J., Li, J., Shen, Z., Ryden, A., Ahlqvist, M., Sunden, M., Karlson, B. W., & Ma, C.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-01
- Volume
- 38
- Issue
- suppl_1
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2762029443
- Cited by
- 78
- References
- 0
- FWCI
- 19.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: P440Ehelp China, a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China. https://app.cochat.ai/papers/10.1093/eurheartj/ehx501.p440
- The paper
- Du, X., Jornten-Karlsson, M., Xu, Y., Guo, J., Li, J., Mei, X., Han, L., Wang, J., Li, J., Shen, Z., Ryden, A., Ahlqvist, M., Sunden, M., Karlson, B. W., & Ma, C. (2017). P440Ehelp China, a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China. European Heart Journal. https://doi.org/10.1093/eurheartj/ehx501.p440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.